Breaking News
February 16, 2019 - Neuroscientists show how the brain responds to texture
February 16, 2019 - Gilead Announces Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
February 16, 2019 - What Can I Do About Sweating? (for Teens)
February 16, 2019 - Companies navigate dementia conversations with older workers
February 16, 2019 - Newly developed stem cell technologies show promise for treating PD patients
February 16, 2019 - Collaborative material research could advance self-assembling nanomaterials
February 16, 2019 - Researchers take major step in creating technology that mimics the human brain
February 16, 2019 - Erasing memories associated with cocaine use reduces drug seeking behavior
February 16, 2019 - Artificial intelligence can accurately predict prognosis of ovarian cancer patients
February 16, 2019 - Racial disparities in cancer deaths on the decline for America
February 16, 2019 - FDA authorizes new interoperable insulin pump for children, adults with diabetes
February 16, 2019 - Coexisting Medical Conditions, Smoking Explain PTSD-CVD Link
February 16, 2019 - Skin Cancer Screening: MedlinePlus Lab Test Information
February 16, 2019 - ‘Happiness’ exercises can boost mood in those recovering from substance use disorder
February 16, 2019 - Cell manipulation could soon halt or reverse aging
February 16, 2019 - Pumped Breast Milk Falls Short of Breastfed Version
February 16, 2019 - Men’s porn habits could fuel partners’ eating disorders, study suggests
February 16, 2019 - Rapid progression of age-related diseases may result from formation of vicious cycles
February 16, 2019 - Immune checkpoint molecule protects against future development of cancer
February 16, 2019 - New method produces hydrogels that have properties similar to cells’ environment
February 16, 2019 - $4.1 million funding for heart research on Valentine’s Day
February 16, 2019 - General anesthesia in early infancy unlikely to have lasting effects on developing brains
February 16, 2019 - New breakthroughs for muscular dystrophy research
February 16, 2019 - First Opinion: Embryo editing for higher IQ is a fantasy. Embryo profiling for it is almost here
February 16, 2019 - Vapers develop cancer-related gene deregulation as cigarette smokers
February 16, 2019 - Bringing Antimicrobial Susceptibility Testing (AST) to the Community
February 16, 2019 - Decolonization protocol after hospital discharge can prevent dangerous infections
February 16, 2019 - H-RT should be the standard of care for men with low risk prostate cancer, study shows
February 16, 2019 - New technique using patients’ own modified cells could help treat Crohn’s disease
February 16, 2019 - Therapeutic endoscopy has an expanding role in the treatment of IBD
February 16, 2019 - Blood clot discovery could lead to development of better treatments for blood diseases
February 16, 2019 - Intervention can increase exclusive breastfeeding rates
February 16, 2019 - New project explores how gaming technologies can help cancer patients communicate better
February 16, 2019 - Catalyst Biosciences Presents Updated Data from Its Phase 2/3 Trial of Subcutaneous Marzeptacog Alfa (Activated) in Individuals with Hemophilia A or B with Inhibitors at the 12th Annual EAHAD Congress
February 16, 2019 - Rerouting nerves during amputation reduces phantom limb pain before it starts
February 16, 2019 - A Hormone Produced When We Exercise Might Help Fight Alzheimer’s
February 16, 2019 - Millions of British people breathe toxic air travelling to GPs
February 16, 2019 - Conformance of genetic characteristics found to be crucial for longer preservation of kidney graft
February 16, 2019 - Researchers use optogenetic tool to control, visualize receptor signals in neural cells
February 16, 2019 - New reversible antiplatelet therapy could reduce risk of blood clots, prevent cancer metastasis
February 16, 2019 - Testosterone is not the only hormone needed for penis development
February 16, 2019 - FDA Advisory Committee Recommends Approval of Spravato (esketamine) Nasal Spray for Adults with Treatment-Resistant Depression
February 15, 2019 - Heart surgery technology developed at Baptist Health debuts after years of secrecy
February 15, 2019 - Prescription Opioids Double Risk of Triggering Fatal Car Crash
February 15, 2019 - New study helps doctors better understand high blood pressure in pregnant women
February 15, 2019 - Beta wave control in Parkinson’s diseased brain could be a potential therapy
February 15, 2019 - Media representations of love may justify gender-based violence in young people
February 15, 2019 - Yoga May Help With Rheumatoid Arthritis Symptoms, Severity
February 15, 2019 - Obstructive sleep apnea linked to inflammation, organ dysfunction
February 15, 2019 - Master your mind: A challenge from WELL for Life
February 15, 2019 - Why Some Brain Tumors Respond to Immunotherapy
February 15, 2019 - Must-Reads Of The Week From Brianna Labuskes
February 15, 2019 - Researchers uncover novel mechanism and potential new therapeutic target for Alzheimer’s
February 15, 2019 - Genetic variations in a fourth gene associated with higher ALL risk in Hispanic children
February 15, 2019 - Disruptive behavioral problems in kindergarten linked with lower employment earnings in adulthood
February 15, 2019 - New bioengineered device enhances the production of T-cells
February 15, 2019 - HDL proteome behaves like a tiny Velcro ball that is rolling on surfaces
February 15, 2019 - Puerto Rican children more likely to have poor or decreasing use of asthma inhalers
February 15, 2019 - Quality of patient care does not improve after physician-hospital integration
February 15, 2019 - Synopsys release new software for implant design and patient-specific planning
February 15, 2019 - 6 out of 10 hip replacements last 25 years or longer
February 15, 2019 - Health Tip: What You Should Know About Antibiotics
February 15, 2019 - New research challenges medical consensus that adenoids and tonsils significantly shrink during teenage years
February 15, 2019 - Discovery of weakness in a rare cancer could be exploited with drugs
February 15, 2019 - UVA scientists find potential explanation for mysterious cell death in Alzheimer’s, Parkinson’s
February 15, 2019 - New rules requiring female athletes to lower testosterone levels are based on flawed data
February 15, 2019 - Researchers comprehensively sequence the human immune system
February 15, 2019 - Researchers study animal venoms to identify new medicines for treating diseases
February 15, 2019 - Movement of wrist bones revealed by MRI and computer modeling
February 15, 2019 - Philips introduces new premium digital X-ray room to help shorten patient wait times
February 15, 2019 - Women fare worse than men following aortic heart surgery, study finds
February 15, 2019 - High-protein and low-calorie diet helps older adults lose weight safely, shows study
February 15, 2019 - Drug microdosing effects may not measure up to big expectations
February 15, 2019 - Discharged, Dismissed: ERs Often Miss Chance To Set Overdose Survivors On ‘Better Path’
February 15, 2019 - A digitized lab environment to be showcased at smartLAB 2019
February 15, 2019 - Scientists uncover main mechanisms of fluconazole drug resistance
February 15, 2019 - New study seeks to understand how colibactin causes cancer
February 15, 2019 - Photoacoustic imaging accurately measures the temperature of deep tissues
February 15, 2019 - Large study finds no association between phthalate exposure and breast cancer risk
February 15, 2019 - New research explains presence of ‘natural’ magnetism in human cells
£500,000 grant could pave way for new antibiotic to battle against drug-resistant superbugs

£500,000 grant could pave way for new antibiotic to battle against drug-resistant superbugs

image_pdfDownload PDFimage_print

A new antibiotic hailed as the “last line of defense” in the battle against drug-resistant superbugs such as MSRA and VRE is taking the next step in development thanks to a UK Government grant of almost £500,000.

Over the next year scientists will develop a catalogue of simplified synthetic versions of a naturally-occurring antibiotic called teixobactin – dubbed a “game changer” when it was discovered in 2015 due to its ability to kill drug-resistant pathogens – by replacing key amino acids at specific points in the antibiotic’s structure to make it easier to recreate.

The creation of an arsenal of new synthetic teixobactin molecules is a vital step in drug development due to a high failure rate when scientists only have a limited number of molecules to work with, and will form one of the key stages of the new research project.

The team of chemists, biologists and clinicians which will use teixobactin as a building block is led by Dr Ishwar Singh at the University of Lincoln, UK, in collaboration with the University of Liverpool.

The £484,000 grant from the Department of Health and Social Care (DHSC) will involve a ‘proof of concept’ trial in test subjects, which if successful, could potentially be used in hospitals as an investigational new medicine and be turned into a drug fit for human use.

Dr Singh, an expert in biological chemistry and specialist in novel drug design and development at the University of Lincoln’s School of Pharmacy, said: “We know that the therapeutic potential of simplified synthetic teixobactin is immense, and our ultimate goal is to have a number of viable drugs from our synthetic teixobactin platform which can be used as a last line of defense against superbugs in hospitals.

“So far we have demonstrated that we can make synthetic versions which are as potent at treating drug-resistant pathogens as the real thing, but we now need to expand our catalog of synthetic teixobactin as a precursor to production on a commercial scale. In drug development, there is a very high failure rate and pinning all hopes on one molecule could be risky. The catalog of molecules we will develop can be put through trials with the ultimate goal of taking a drug fit for human use to the clinic.”

The grant is being awarded by DHSC as part of the Small Business Research Initiative (SBRI), a £10 million investment to address the problem of antimicrobial resistance.

The work builds on the success of Dr Singh’s pioneering research to tackle antimicrobial resistance over the past three years. Earlier this year, the research team were the first in the world to successfully create simplified, synthetic forms of teixobactin. One of these was successfully used to treat a bacterial infection in mice. Importantly, the synthetic teixobactin offered dual benefits of both clearing the bacterial infection and minimizing its severity, which was not the case for the clinically-used antibiotic, moxifloxacin, used as a control study.

Once developed, the teixobactin antibiotic will be the first new class of antibiotic drug in 30 years.

It has been predicted that by 2050 an additional 10 million people will succumb to drug resistant infections each year. The development of new antibiotics which can be used as a last resort when other drugs are ineffective is therefore a crucial area of study for healthcare researchers around the world.

Professor William Hope and Dr Shampa Das from the Centre for Antimicrobial Pharmacodynamics at the University of Liverpool will undertake the in vivo evaluations. Professor Hope said: “We are delighted to collaborate with Dr Singh and the University of Lincoln to help develop new antibiotics that address unmet medical need related to antimicrobial resistance. The teixobactin project complements our other programs for development of new antibiotics for multidrug-resistant bacterial and fungal diseases.”

The next step in the research will be the production of a so-called ‘investigational drug or medicine’ – a drug which is developed for safe testing in humans followed by clinical trials and new drug approval by regulatory bodies.

Source:

http://www.lincoln.ac.uk/

Tagged with:

About author

Related Articles